Liposomal drug products and recent advances in the synthesis of supercritical fluid-mediated liposomes

Nanomedicine

Volumn 8, Issue 9, 2013, Pages 1529-1548

  Karn, Pankaj Ranjan ^a   Cho, Wonkyung ^a   Hwang, Sung Joo ^a  

^a Yonsei University   (South Korea)

Author keywords

conventional method; industrial scale; liposomal drug product; liposome

Indexed keywords

AMIKACIN; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ARIKACE; BUPIVACAINE; CARBON DIOXIDE; CISPLATIN; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ENDOTAG 1; HEMAGGLUTININ; HEPATITIS A ANTIGEN; HEPATITIS A VACCINE; INFLUENZA VACCINE; LIPO DOX; LIPOPLATIN; LIPOSOMAL DRUG PRODUCT; LIPOSOME; MORPHINE SULFATE; PACLITAXEL; THERMODOX; UNCLASSIFIED DRUG; VERTEPORFIN; VINCRISTINE SULFATE; DRUG CARRIER; SOLUTION AND SOLUBILITY; SOLVENT;

DRUG FORMULATION; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; SUPERCRITICAL FLUID; CHEMISTRY; HUMAN; SOLUTION AND SOLUBILITY; THERAPEUTIC USE;

DRUG CARRIERS; HUMANS; LIPOSOMES; SOLUTIONS; SOLVENTS;

EID: 84893161274     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.13.131     Document Type: Review

References (72)

1. Bangham A, Standish M, Watkins J. Diffusion of univalent ions across the lamellae of swollen phospholipids. J. Mol. Biol. 13(1), 238-252 (1965).
2. Sessa G, Weissmann G. Phospholipid spherules (liposomes) as a model for biological membranes. J. Lipid Res. 9(3), 310-318 (1968).
3. Gregoriadis G, Ryman B. Liposomes as carriers of enzymes or drugs: A new approach to the treatment of storage diseases. J. Biochem. 124(5), 58P (1971).
4. Gregoriadis G. Drug entrapment in liposomes. FEBS Lett. 36(3), 292-296 (1973).
5. Gregoriadis G. The carrier potential of liposomes in biology and medicine (first of two parts). N. Engl. J. Med. 295(13), 704-710 (1976).
6. Gregoriadis G. The carrier potential of liposomes in biology and medicine (second of two parts). N. Engl. J. Med. 295(14), 765-770 (1976).
7. Chang HI, Yeh MK. Clinical development of liposome-based drugs: Formulation, characterization, and therapeutic efficacy. Int. J. Nanomedicine 7, 49-60 (2012).
8. Meure LA, Foster NR, Dehghani F. Conventional and dense gas techniques for the production of liposomes: A review. AAPS PharmSciTech 9(3), 798-809 (2008).
9. New RRC. Introduction. In: Liposomes: A Practical Approach. New RRC (Ed.). Oxford University Press, Oxford, UK, 22-25 (1990).
10. Samad A, Sultana Y, Aqil M. Liposomal drug delivery systems: An update review. Curr. Drug Deliv. 4(4), 297-305 (2007).
11. Szoka F Jr, Papahadjopoulos D. Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proc. Natl Acad. Sci. USA 75(9), 4194-4198 (1978).
12. Hope M, Bally M, Webb G, Cullis P. Production of large unilamellar vesicles by a rapid extrusion procedure. Characterization of size distribution, trapped volume and ability to maintain a membrane potential. Biochim. Biophys. Acta 812(1), 55-65 (1985).
13. Wagner A, Vorauer-Uhl K. Liposome technology for industrial purposes. J. Drug Deliv. 2011, 591325 (2011).
14. Bridson R, Santos R, AlDuri B, McAllister S, Robertson J, Alpar H. The preparation of liposomes using compressed carbon dioxide: Strategies, important considerations and comparison with conventional techniques. J. Pharm. Pharmacol. 58(6), 775-785 (2006).
15. Patil SD, Burgess DJ. Liposome: Design and manufacturing. In: Injectable Dispersed Systems Formulation, Processing, and Performance. Burgess DJ (Ed.). Taylor and Francis, FL, USA, 249-284 (2005).
16. Allen TM, Cullis PR. Liposomal drug delivery systems: From concept to clinical applications. Adv. Drug Deliv. Rev. 65(1), 36-48 (2013).
17. Slingerland M, Guchelaar HJ, Gelderblom H. Liposomal drug formulations in cancer therapy: 15 years along the road. Drug Discov. Today 17(3), 160-166 (2012).
18. Song G, Wu H, Yoshino K, Zamboni WC. Factors affecting the pharmacokinetics and pharmacodynamics of liposomal drugs. J. Liposome Res. 22(3), 177-192 (2012).
19. Lasch J, Weissig V, Brandl M. Preparation of liposomes. In: Liposomes: A Practical Approach. Torchilin V, Weissig V (Eds). Oxford University Press, Oxford, UK (2003).
20. Batzri S, Korn ED. Single bilayer liposomes prepared without sonication. Biochim. Biophys. Acta 298(4), 1015-1019 (1973).
21. Deamer D, Bangham A. Large volume liposomes by an ether vaporization method. Biochim. Biophys. Acta 443(3), 629-634 (1976).
22. Karn PR, Vanic Z, Pepic I, Škalko-Basnet N. Mucoadhesive liposomal delivery systems: The choice of coating material. Drug Dev. Ind. Pharm. 37(4), 482-488 (2011).
23. Lesoin L, Crampon C, Boutin O, Badens E. Preparation of liposomes using the supercritical anti-solvent (SAS) process and comparison with a conventional method. J. Supercrit. Fluids 57(2), 162-174 (2011).
24. Cha KH, Cho KJ, Kim MS, et al.: Enhancement of the dissolution rate and bioavailability of fenofibrate by a melt-Adsorption method using supercritical carbon dioxide. Int. J. Nanomedicine 7, 5565-5575 (2012).
25. Kim MS, Jin SJ, Kim JS, et al.: Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process. Eur. J. Pharm. Biopharm. 69(2), 454-465 (2008).
26. Kim MS, Kim JS, Park HJ, Cho WK, Cha KH, Hwang SJ. Enhanced bioavailability of sirolimus via preparation of solid dispersion nanoparticles using a supercritical antisolvent process. Int. J. Nanomedicine 6, 2997-3009 (2011).
27. Park J, Cho W, Cha KH, Ahn J, Han K, Hwang SJ. Solubilization of the poorly-water soluble drug, telmisartan, using supercritical anti-solvent (SAS) process. Int. J. Pharm. 441(1-2), 50-55 (2013).
28. Karn PR, Cho W, Park HJ, Park JS, Hwang SJ. Characterization and stability studies of a novel liposomal cyclosporin A prepared using the supercritical fluid method: Comparison with the modified conventional Bangham method. Int. J. Nanomedicine 8, 365-377 (2013).
29. Taylor L. Supercritical Fluid Extraction. Wiley Interscience Publication, NY, USA, 1-26 (1996).
30. Hannay J, Hogarth J. On the solubility of solids in gases. Proc. Roy. Soc. London 29, 324-327 (1879).
31. Naylor A, Lewis AL, Illum L. Supercritical fluid-mediated methods to encapsulate drugs: Recent advances and new opportunities. Ther. Deliv. 2(12), 1551-1565 (2011).
32. Herrero M, Mendiola JA, Cifuentes A, Ibáñez E. Supercritical fluid extraction: Recent advances and applications. J. Chromatogr. A 1217(16), 2495-2511 (2010).
33. Byrappa K, Ohara S, Adschiri T. Nanoparticles synthesis using supercritical fluid technology-Towards biomedical applications. Adv. Drug Deliv. Rev. 60(3), 299-327 (2008).
34. Lesoin L, Crampon C, Boutin O, Badens E. Development of a continuous dense gas process for the production of liposomes. J. Supercrit. Fluids 60, 51-62 (2011).
35. Zhong J, Dai L. Liposomal preparation by supercritical fluids technology. Afr. J. Biotechnol. 10(73), 16406-16413 (2011).
36. Kompella UB, Koushik K. Preparation of drug delivery systems using supercritical fluid technology. Crit. Rev. Ther. Drug 18(2), 173-199 (2001).
37. Frederiksen L, Anton K, Hoogevest PV, Barratt BJ, Leuenberger H. Use of supercritical carbon dioxide for preparation of pharmaceutical formulations. Presented at: Proceeding of 3rd International Symposium on Supercritical Fluids (Volume 3). Strasbourg, France, 17-19 October 1994.
38. Frederiksen L, Anton K, Hoogevest PV, Keller HR, Leuenberger H. Preparation of liposomes encapsulating watersoluble compounds using supercritical carbon dioxide. J. Pharm. Sci. 86(8), 921-928 (1997).
39. Castor TP. Phospholipid nanosomes. Curr. Drug Deliv. 2(4), 329-340 (2005).
40. Phillips EM, Stella VJ. Rapid expansion from supercritical solutions: Application to pharmaceutical processes. Int. J. Pharm. 94(1-3), 1-10 (1993).
41. Pasquali I, Bettini R. Are pharmaceutics really going supercritical? Int. J. Pharm. 364(2), 176-187 (2008).
42. Girotra P, Singh SK, Nagpal K. Supercritical fluid technology: A promising approach in pharmaceutical research. Pharm. Dev. Technol. 18(1), 22-38 (2013).
43. Wen Z, Liu B, Zheng Z, You X, Pu Y, Li Q. Preparation of liposomes entrapping essential oil from Atractylodes macrocephala Koidz by modified RESS technique. Chem. Eng. Res. Des. 88(8), 1102-1107 (2010).
44. Zhang W, Sun Y, Li Y, Shen R, Ni H, Hu D. Preparation and influencing factors of sirolimus liposome by supercritical fluid. Artif. Cells. Blood Substit. Immobil. Biotechnol. 40(1-2), 62-65 (2012).
45. Gallagher P, Coffey M, Krukonis V, Klasutis N. Gas antisolvent recrystallization: New process to recrystallize compounds insoluble in supercritical fluids. In: Supercritical Fluid Science and Technology (Volume 406). Johnston KP, Penninger JML (Eds). American Chemical Society, DC, USA, 334-354 (1989).
46. Dehghani F, Foster N. Dense gas anti-solvent processes for pharmaceutical formulation. Curr. Opin. Solid State Mater. Sci. 7(4), 363-369 (2003).
47. Kadimi US, Balasubramanian DR, Ganni UR, Balaraman M, Govindarajulu V. In vitro studies on liposomal amphotericin B obtained by supercritical carbon dioxide-mediated process. Nanomedicine 3(4), 273-280 (2007).
48. Ghatnur SM, Sonale RS, Balaraman M, Kadimi US. Engineering liposomes of leaf extract of seabuckthorn (SBT) by supercritical carbon dioxide (SC-CO2)-mediated process. J. Liposome Res. 22(3), 215-223 (2012).
49. Naik S, Patel D, Surti N, Misra A. Preparation of PEGylated liposomes of docetaxel using supercritical fluid technology. J. Supercrit. Fluids 54(1), 110-119 (2010).
50. Naik S, Patel D, Chuttani K, Mishra AK, Misra A. In vitro mechanistic study of cell death and in vivo performance evaluation of RGD grafted PEGylated docetaxel liposomes in breast cancer. Nanomedicine 8(6), 951-962 (2012).
51. Lasic DD. Novel applications of liposomes. Trends Biotechnol. 16(7), 307-321 (1998).
52. Xia F, Jin H, Zhao Y, Guo X. Preparation of coenzyme Q10 liposomes using supercritical anti-solvent technique. J. Microencapsul. 29(1), 21-29 (2012).
53. Otake K, Shimomura T, Goto T, et al.: Preparation of liposomes using an improved supercritical reverse phase evaporation method. Langmuir 22(6), 2543-2550 (2006).
54. Bleich J, Müller B, Wassmus W. Aerosol solvent extraction system-A new microparticle production technique. Int. J. Pharm. 97(1), 111-117 (1993).
55. Kunastitchai S, Pichert L, Sarisuta N, Müller BW. Application of aerosol solvent extraction system (ASES) process for preparation of liposomes in a dry and reconstitutable form. Int. J. Pharm. 316(1), 93-101 (2006).
56. Bleich J, Müller B Production of drug loaded microparticles by the use of supercritical gases with the aerosol solvent extraction system (ASES) process. J. Microencapsul. 13(2), 131-139 (1996).
57. Kunastitchai S, Sarisuta N, Panyarachun B, Müller BW. Physical and chemical stability of miconazole liposomes prepared by supercritical aerosol solvent extraction system (ASES) process. Pharm. Dev. Technol. 12(4), 361-370 (2007).
58. Otake K, Imura T, Sakai H, Abe M. Development of a new preparation method of liposomes using supercritical carbon dioxide. Langmuir 17(13), 3898-3901 (2001).
59. Imura T, Gotoh T, Otake K, et al.: Control of physicochemical properties of liposomes using a supercritical reverse phase evaporation method. Langmuir 19(6), 2021-2025 (2002).
60. Imura T, Otake K, Hashimoto S, et al.: Preparation and physicochemical properties of various soybean lecithin liposomes using supercritical reverse phase evaporation method. Colloid Surf. B 27(2), 133-140 (2003).
61. Aburai K, Yagi N, Yokoyama Y, et al.: Preparation of liposomes modified with lipopeptides using a supercritical carbon dioxide reverse-phase evaporation method. J. Oleo Sci. 60(5), 209-215 (2011).
62. Otake K, Shimomura T, Goto T, et al.: One-step preparation of chitosan-coated cationic liposomes by an improved supercritical reverse-phase evaporation method. Langmuir 22(9), 4054-4059 (2006).
63. Sakai H, Gotoh T, Imura T, Sakai K, Otake K, Abe M. Preparation and properties of liposomes composed of various phospholipids with different hydrophobic chains using a supercritical reverse phase evaporation method. J. Oleo Sci. 57(11), 613-621 (2008).
64. Martin FJ. Case study: Doxil, the development of PEGylated liposomal doxorubicin. In: Injectable Dispersed Systems Formulation, Processing, and Performance. Burgess DJ (Ed.). Taylor and Francis, FL, USA, 427-471 (2005).
65. Chen JR, Yang YC, Chen TC, et al.: Salvage chemotherapy in recurrent cervical cancer with biweekly PEGylated liposomal doxorubicin (Lipo-Dox). Taiwan J. Obstet. Gynecol. 47(3), 322-326 (2008).
66. Swenson CE, Perkins WR, Roberts P, Janoff AS. Liposome technology and the development of Myocet™ (Liposomal doxorubicin citrate). The Breast 10(Suppl. 2), 1-7 (2001).
67. Allen TM, Martin FJ. Advantages of liposomal delivery systems for anthracyclines. Semin. Oncol. 31(Suppl. 13), 5-15 (2004).
68. Bekersky I, Fielding RM, Buell D, Lawrence I. Lipid-based amphotericin B formulations: From animals to man. Pharm. Sci. Technolol. Today 2(6), 230-236 (1999).
69. Petre CE, Dittmer DP. Liposomal daunorubicin as treatment for Kaposi's sarcoma. Int. J. Nanomedicine 2(3), 277-288 (2007).
70. Bressler NM, Bressler SB. Photodynamic therapy with verteporfin (Visudyne): Impact on ophthalmology and visual science. Invest. Ophthalmol. Vis. Sci. 41(3), 624-628 (2000).
71. Bovier PA. Epaxal®: A virosomal vaccine to prevent hepatitis A infection. Expert Rev. Vaccines 7(8), 1141-1150 (2008).
72. Mischler R, Metcalfe IC. Inflexal®V a trivalent virosome subunit influenza vaccine: Production. Vaccine 20(Suppl. 5), B17-B23 (2002).